Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$141.35 +1.7%	$139.58	$122.80 ▼ $219.34	$4.09B	0.67	287,116 shs	209,949 shs
NUVL Nuvalent	$80.50 +3.2%	$74.99	$55.54 ▼ $113.51	$5.78B	1.31	503,185 shs	558,641 shs
OGN Organon & Co.	$10.16 +1.1%	$9.72	$8.01 ▼ $23.10	$2.64B	0.6	3.52 million shs	4.12 million shs
SPRY ARS Pharmaceuticals	$16.75 +4.1%	$14.71	$8.65 ▼ $18.90	$1.65B	0.9	1.34 million shs	1.28 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	+1.13%	-3.24%	+9.41%	-23.20%	-23.73%
NUVL Nuvalent	+2.24%	+1.47%	+5.95%	+10.72%	+3.31%
OGN Organon & Co.	+3.51%	+0.76%	+8.91%	-32.02%	-50.62%
SPRY ARS Pharmaceuticals	-7.79%	-4.11%	+9.60%	+23.30%	+84.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KRYS Krystal Biotech	4.6267 of 5 stars	3.5	1.0	0.0	4.7	3.1	2.5	1.9
NUVL Nuvalent	2.8405 of 5 stars	3.5	3.0	0.0	0.0	2.4	3.3	0.0
OGN Organon & Co.	4.897 of 5 stars	3.3	4.0	1.7	3.7	1.7	3.3	2.5
SPRY ARS Pharmaceuticals	3.0867 of 5 stars	3.6	1.0	0.0	0.0	2.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRYS Krystal Biotech	3.00	Buy	$211.13	49.36% Upside
NUVL Nuvalent	3.17	Buy	$119.60	48.57% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	77.17% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	85.07% Upside

Current Analyst Ratings Breakdown

Latest SPRY, KRYS, OGN, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	NUVL Nuvalent	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	NUVL Nuvalent	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $112.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/24/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
6/24/2025	NUVL Nuvalent	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $140.00
6/24/2025	NUVL Nuvalent	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $130.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRYS Krystal Biotech	$290.52M	14.06	$4.77 per share	29.64	$32.90 per share	4.30
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
OGN Organon & Co.	$6.40B	0.41	$5.18 per share	1.96	$1.83 per share	5.55
SPRY ARS Pharmaceuticals	$89.15M	18.45	$0.01 per share	2,060.63	$2.64 per share	6.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRYS Krystal Biotech	$89.16M	$4.16	33.98	14.02	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.53	2.72	1.01	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest SPRY, KRYS, OGN, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.79%	N/A	2.78%	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest SPRY, KRYS, OGN, and NUVL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRYS Krystal Biotech	N/A	9.65	9.27
NUVL Nuvalent	N/A	14.48	14.48
OGN Organon & Co.	16.49	1.67	1.15
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRYS Krystal Biotech	86.29%
NUVL Nuvalent	97.26%
OGN Organon & Co.	77.43%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
KRYS Krystal Biotech	13.70%
NUVL Nuvalent	10.20%
OGN Organon & Co.	1.40%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
OGN Organon & Co.	4,000	259.96 million	256.32 million	Not Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

SPRY, KRYS, OGN, and NUVL Headlines

Recent News About These Companies

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 Shares

July 2 at 5:18 AM | insidertrades.com

James E. Flynn Sells 740,149 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

July 1 at 6:05 PM | marketbeat.com

Peregrine Capital Management LLC Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

July 1 at 5:40 AM | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What Happened

June 30 at 12:59 PM | marketbeat.com

Lisanti Capital Growth LLC Buys New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 29 at 6:33 AM | marketbeat.com

55,714 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Matisse Capital

June 28, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to "Hold" at Wall Street Zen

June 28, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Wall Street Zen

June 28, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - Still a Buy?

June 27, 2025 | marketbeat.com

Leerink Partnrs Analysts Raise Earnings Estimates for SPRY

June 26, 2025 | americanbankingnews.com

Q2 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

June 25, 2025 | marketbeat.com

Harbour Capital Advisors LLC Purchases New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 25, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLC

June 25, 2025 | marketbeat.com

What is Leerink Partnrs' Estimate for SPRY FY2029 Earnings?

June 25, 2025 | americanbankingnews.com

Brokers Offer Predictions for SPRY FY2029 Earnings

June 24, 2025 | marketbeat.com

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $240,000.00 in Stock

June 23, 2025 | americanbankingnews.com

Janney Montgomery Scott LLC Boosts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 23, 2025 | marketbeat.com

Eric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

June 20, 2025 | marketbeat.com

249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource Council

June 20, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

June 16, 2025 | marketbeat.com

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

June 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop

SPRY, KRYS, OGN, and NUVL Company Descriptions

Krystal Biotech NASDAQ:KRYS

$141.35 +2.34 (+1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$140.45 -0.90 (-0.64%)

As of 05:32 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Nuvalent NASDAQ:NUVL

$80.50 +2.49 (+3.19%)

Closing price 04:00 PM Eastern

Extended Trading

$80.44 -0.06 (-0.07%)

As of 05:08 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Organon & Co. NYSE:OGN

$10.16 +0.11 (+1.09%)

Closing price 03:59 PM Eastern

Extended Trading

$10.05 -0.11 (-1.07%)

As of 05:23 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

ARS Pharmaceuticals NASDAQ:SPRY

$16.75 +0.66 (+4.10%)

Closing price 04:00 PM Eastern

Extended Trading

$16.73 -0.02 (-0.15%)

As of 05:29 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time